Pfizer joins Sanofi on the C. difficile failure train after its vaccine flopped a PhIII study
Big Pharma has been trying to come up with a vaccine for C. difficile infection for years, but one more program joined the heap of recent failures.
Pfizer reported that a Phase III study of its experimental shot did not meet its primary endpoint for preventing the infection, the company said early Tuesday. Pfizer’s plans for the candidate, dubbed PF-06425090, are not yet clear, but the company hinted at a strategy centered around a signal shown in some secondary endpoints.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.